Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 3/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 8/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | NPY1R | P25929 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13564777 | 0.83 | SLC2A1 (0.45) | NPY5RSLC2A1HTR1AADRA1DADRA1A | |
| SCHEMBL10113867 | 0.83 | ALDH1A1 (0.40) | GRIA1NPY5RNPY1R | |
| SCHEMBL13565657 | 0.81 | CA2 (0.49) | GRIA1SLC2A1 | |
| SCHEMBL15826444 | 0.79 | S1PR2 (0.52) | SLC2A1HTR1AADRA1DADRA1AADRA1B | |
| Hydrochloric Acid SCHEMBL17260150 | 0.78 | SLC2A1 (0.52) | SLC2A1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL11935003 | 0.77 | LOXL2 (0.54) | SLC2A1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL3265308 | 0.76 | LOXL2 (0.49) | SLC2A1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL13565855 | 0.76 | HTR1A (0.56) | GRIA1NPY5RHTR1AADRA1DADRA1A | |
| SCHEMBL13105496 | 0.75 | GRIA1 (0.46) | GRIA1NPY5RSLC2A1NPY1R | |
| SCHEMBL13565089 | 0.74 | NPY5R (0.55) | NPY5RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139518-B2 | Amine derivative having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2015-09-22 | — | — | US | disclosed |
| US-8299265-B2 | Amine derivatives having NPY Y5 receptor antagonistic activity and the uses thereof | SHIONOGI & CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20100267945-A1 | AMINE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267945-A1 | AMINE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | GRIA1 413/4885NPY5R 1/4885SLC2A1 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.